Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.
about
Impact of polysomy 17 on HER2 testing of invasive breast cancer patientsMechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome ItHER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneityLimited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.Raf-1 oncogenic signaling is linked to activation of mesenchymal to epithelial transition pathway in metastatic breast cancer cellsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations.Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.Updated UK Recommendations for HER2 assessment in breast cancer.Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticityThe Clinicopathologic and Prognostic Value of Altered Chromosome 17 Centromere Copy Number in HER2 Fish Equivocal Breast CarcinomasIn situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendationsPalindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumorsQuantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatmentSignificant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization.Adverse prognostic impact of intratumor heterogeneous HER2 gene amplification in patients with esophageal adenocarcinoma89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast TumorsFISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics.HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status.Variability in hormone and growth factor receptor expression in primary versus recurrent, metastatic, and post-neoadjuvant breast carcinoma.Epistatic interactions and drug response.HER2 assessment by silver in situ hybridization: where are we now?HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Automated Image Analysis of HER2 Fluorescence In Situ Hybridization to Refine Definitions of Genetic Heterogeneity in Breast Cancer Tissue.Comparison of HER2 testing among laboratories: Our experience with review cases retested at Moffitt Cancer Center in a two-year period.The assessment of HER2 status in breast cancer: the past, the present, and the future.'Non-classical' HER2 FISH results in breast cancer: a multi-institutional study.Virtual tissue microarrays: a novel and viable approach to optimizing tissue microarrays for biomarker research applied to ductal carcinoma in situ.Robust and accurate digital measurement for HER2 amplification in HER2 equivocal breast cancer diagnosis.Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma.Reply to 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'.Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis.'Genetic heterogeneity' in HER2/neu testing by fluorescence in situ hybridization: a study of 2,522 cases.Letter to the editor regarding 'Seol H, Lee HJ, Choi Y, et al. Intratumoural heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'.Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance.HER2 intratumoral heterogeneity is independently associated with incomplete response to anti-HER2 neoadjuvant chemotherapy in HER2-positive breast carcinoma.Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers.HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer.Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue.
P2860
Q24619955-ABF58535-141B-4311-9BC8-53854DF80016Q26752780-4A04D14A-5AC6-48D9-A80B-99F272362995Q27006811-E7B8E6F3-6230-42B0-BBB8-7C0AE48333BBQ33648936-19AD1C35-CD2A-4BF0-B228-35F6EDADDE4AQ33759701-A8366A69-FB2A-4A7D-AD56-095FB776D074Q33862786-7182D080-805C-4902-A2C5-55DF86DE14B4Q34202609-FAE84033-7FDB-48F7-93ED-532B0ABD0519Q34458036-5BB2A675-53A4-4E5C-BD9C-4F99E6541BA8Q35048548-7B063578-1F89-45E5-B1EA-CAD64CD621E4Q35124176-59759B1D-BD86-49C3-A924-B06177805615Q35687706-B3BAA8FD-8543-4BCA-B273-D37AA8705DC2Q36109108-D0F24198-8409-443E-BF5A-DB12DD680ABCQ36203525-A17207F4-8522-40C0-8AED-19F1DB8A1880Q36283885-C8598FAB-B372-412B-B1C4-5C1210626B57Q36707771-1180D29B-24D4-40C6-BDBC-85D19337E7C2Q36801203-1EC87BB0-58EB-45BC-8FA1-187B72EA7F1FQ36910400-CAD646A2-B27B-4AD6-A7AD-EC63A70D6F93Q37148669-4A675F32-6AFF-4275-85F1-41DCD78E9404Q37406841-CFA0CC34-9B47-413B-AD71-6F9F697177E3Q37588232-18385B6E-C6EF-4B44-880A-F00B43572DEAQ38000948-7E4EDFF1-AFBB-49E8-973C-3784B81D622AQ38150749-2032F584-046D-45AE-AEA6-FF11C083FBACQ38314355-958BA7E8-E5BB-4BFE-A1A5-F23E4544E40BQ38326102-85F6DBDA-24C9-4F73-95F9-FC698794E4C5Q38656185-43CF546D-F819-4653-860C-BBF7EE5D19BBQ38681307-646FE71C-3B1A-461C-A010-23A26E5537EDQ38802932-91C43B29-580A-49ED-8953-A7AD0BF1F74BQ39292642-6D5A4BBD-B62A-4A55-9AF8-CC93B3F73A04Q40152768-767EDE85-4874-4431-8AFF-1BCBF735E5F7Q40490703-6EF25D14-C81F-42AB-BE2B-4436B5AF6D42Q43551349-E0A156AF-7F2D-4D87-B4A0-67960C3B7E89Q43962627-B9795DEF-045B-41E4-8762-2D0D72955827Q44505402-A84843F1-6A99-4A7A-98A2-722D529AB04EQ44639508-53AE46CD-82D2-475B-9ED8-91F6A1014F3AQ44667966-D4AF78EA-9AA0-4622-9F89-A3B12C5A2750Q44838384-DE878867-4404-48BD-993D-ADBB40AD9C1EQ47965547-5B2E5924-5F65-4132-B1A9-4096BD205FCAQ49498310-5E8C87FD-5C9A-4DE9-A34B-7EC588D0A35BQ51175484-2B7A98B8-A6E7-46D7-B4E3-18D554BFB54BQ51556494-3D5DCEC0-B0CC-4253-B652-5338CEEEE8C1
P2860
Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Heterogeneous HER2 gene amplif ...... linically relevant definition.
@en
Heterogeneous HER2 gene amplif ...... linically relevant definition.
@nl
type
label
Heterogeneous HER2 gene amplif ...... linically relevant definition.
@en
Heterogeneous HER2 gene amplif ...... linically relevant definition.
@nl
prefLabel
Heterogeneous HER2 gene amplif ...... linically relevant definition.
@en
Heterogeneous HER2 gene amplif ...... linically relevant definition.
@nl
P2093
P2860
P356
P1476
Heterogeneous HER2 gene amplif ...... linically relevant definition.
@en
P2093
Alastair I Bartlett
Alex Maclellan
Annette Hasenburg
Christos Markopoulos
Cornelis J H van de Velde
Daniel Rea
Fiona M Campbell
Jane Starcyznski
John M S Bartlett
Tammy Robson
P2860
P304
P356
10.1309/AJCP0EN6AQMWETZZ
P407
P577
2011-08-01T00:00:00Z